Targeting SLC7A11/xCT improves radiofrequency ablation efficacy of HCC by dendritic cells mediated anti-tumor immune response
Related Experiment Video
Updated: May 7, 2025

Evaluating Targeting Accuracy in the Focal Plane for an Ultrasound-guided High-intensity Focused Ultrasound Phased-array System
Published on: March 6, 2019
Yuzhao Jin1, Songhua Cai2, Yang Zhou3
1Postgraduate Training Base Wenzhou Medical University Wenzhou China.
Abstract:
After RFA treatment in patients with liver cancer, the expression of SLC7A11/xCT and the proportion of DCs in the TME were significantly increased. SLC7A11/xCT is a poor prognostic marker for liver cancer and is mainly expressed in DCs in the TME. Targeting xCT in DCs combined with RFA significantly enhances anti-tumor immunity, suppressing tumor growth and offering a promising strategy for improved therapeutic outcomes in liver cancer.
Related Concept Videos
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Dose-Response Relationship: Selectivity and Specificity

